



EUROPEAN  
SOCIETY OF  
CARDIOLOGY®

# European Heart Journal

Volume 38 No. 15 April 2017

## ISSUE @ A GLANCE



From systemic and pulmonary hypertension to heart failure: novel drugs and devices  
*T.F. Lüscher*

1087

## CardioPulse

Blood pressure targets

*P.K. Whelton, J. Chen, and M. "Tonette" Krousel-Wood*

1091

The future of Heart Failure in Diabetes

*M. Nicholls*

1093

Make regeneration great again; stronger together

*A. Behfar and A. Terzic*

1094

Cell-based cardiac regeneration

*M.Y. Emmert*

1095

Italian Society of Cardiology Annual Congress 2016

*F. Romeo*

1099

Davide Capodanno MD PhD

1100

## REVIEWS



Clinical update

Interventional procedures and future drug therapy for hypertension

*M.D. Lobo, P.A. Sobotka, and A. Pathak*

1101

Masked hypertension: understanding its complexity

*S.S. Franklin, E. O'Brien, and J.A. Staessen*

1112

## FAST TRACK CLINICAL RESEARCH



Heart failure/cardiomyopathy

Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimulator in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study

*B. Pieske, A.P. Maggioni, C.S.P. Lam, E. Pieske-Kraigher, G. Filippatos, J. Butler, P. Ponikowski, S.J. Shah, S.D. Solomon, A.-V. Scalise, K. Mueller, L. Roessig, and M. Gheorghiade*

1119

Editorial

What can we learn from SOCRATES: more questions than answers?

*J.G.F. Cleland and C. Mueller*

1128

## CLINICAL RESEARCH

Heart failure/cardiomyopathy

Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF

*M. Böhm, R. Young, P.S. Jhund, S.D. Solomon, J. Gong, M.P. Lefkowitz, A.R. Rizkala, J.L. Rouleau, V.C. Shi, K. Swedberg, M.R. Zile, M. Packer, and J.J.V. McMurray*

1132

Editorial


Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction

*R. Maria Bruno and S. Taddei*

1144



## Pulmonary circulation



**SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension**  
*N. Galiè, P. Jansa, T. Pulido, R.N. Channick, M. Delcroix, H.-A. Ghofrani, F.-O. Le Brun, S. Mehta, L. Perchenet, L.J. Rubin, B.K.S. Sastry, G. Simonneau, O. Sitbon, R. Souza, and A. Torbicki*

1147

### Editorial

**Randomized controlled trials: a solid platform for observational research**

*P.J. Leary and E.R. Swenson*

1156

**Effect of breathing oxygen-enriched air on exercise performance in patients with precapillary pulmonary hypertension: randomized, sham-controlled cross-over trial**

*S. Ulrich, E.D. Hasler, S. Saxer, M. Furian, S. Müller-Mottet, S. Keusch, and K.E. Bloch*

1159

### Editorial

**Just air good enough in pulmonary hypertension?**

*V. van Empel, C. Knackstedt, P. van Paassen, and H.-P. Brunner-La Rocca*

1169

## CARDIOVASCULAR FLASHLIGHTS

**Giant tubercular pericardial cyst leading to tamponade physiology**

*H.K. Yadav, S.K. Dwivedi, A. Pradhan, and V. Devenraj*

1143

**Ectopic left ventricular apical diverticulum**

*S. Prasad, G. Singh, D.S. Kumar, S. Sivasankaran, and V.K. Ajit Kumar*

1172



Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site

<https://academic.oup.com/eurheartj>



[www.eurheartj.org](http://www.eurheartj.org)